Share on StockTwits
 

Becton Dickinson & Co. (NYSE:BDX) was upgraded by stock analysts at McLean Capital Management from a “neutral” rating to a “buy” rating in a report issued on Friday, American Banking News.com reports.

Shares of Becton Dickinson & Co. (NYSE:BDX) traded down 0.47% on Friday, hitting $114.98. The stock had a trading volume of 628,485 shares. Becton Dickinson & Co. has a 52 week low of $86.38 and a 52 week high of $115.91. The stock’s 50-day moving average is $110.4 and its 200-day moving average is $105.3. The company has a market cap of $22.194 billion and a P/E ratio of 24.40.

Becton Dickinson & Co. (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.42 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.30 by $0.12. The company had revenue of $2.00 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter last year, the company posted $1.35 earnings per share. Becton Dickinson & Co.’s revenue was up 6.1% compared to the same quarter last year. On average, analysts predict that Becton Dickinson & Co. will post $6.23 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $0.545 per share. This represents a $2.18 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend is Thursday, March 6th.

Several other analysts have also recently commented on the stock. Analysts at Raymond James upgraded shares of Becton Dickinson & Co. from an “underperform” rating to a “market perform” rating in a research note on Wednesday, February 5th. Separately, analysts at Leerink Swann raised their price target on shares of Becton Dickinson & Co. from $107.00 to $113.00 in a research note on Wednesday, February 5th. Finally, analysts at Piper Jaffray upgraded shares of Becton Dickinson & Co. to an “overweight” rating in a research note on Tuesday, January 21st. They now have a $18.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $104.68.

Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.